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Corticosteroids are effective anti-inflammatory medications that are recommended for the
control of persistent asthma. Little, however, is known about their influence on the perception
of dyspnea, which, in turn, is important to the successful self-management of asthma. This
paper provides a synopsis of available studies examining the impact of corticosteroids on the
sensitivity to perceive dyspnea and presents possible mechanisms underlying this relationship.
The results of these investigations are conflicting with some studies showing improved
perception and other studies showing worsened perception of dyspnea after corticosteroid
treatment. Thus, firm conclusions cannot be derived from the currently available data.
Implications for future research, which is required to increase our understanding of potential
influences of corticosteroids on the perception of dyspnea, are provided.
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Corticosteroids are commonly prescribed anti-inflammatory
medications used in the treatment of various diseases that
are mediated by the immune system, including rheumatoid
arthritis, inflammatory bowel syndrome, allergies and
asthma. Since asthma is characterized by airway inflamma-
tion even in mild cases, inhaled corticosteroids (ICS) have
been recommended as first-line treatment for patients who
need more than occasional inhalations of short acting
bronchodilators.1 In a previous meta-analysis, Sin et al.2
confirmed that ICS are the single most effective therapy for
patients with asthma; this is true both for pediatric and
adult patients. In their analysis of 69 trials it was found that
ICS reduced exacerbations by approximately 55% compared
to placebos or short-acting b2 agonists and improved the
lung function, as measured by the forced expiratory volume
in 1 s (FEV1), by nearly 330mL in the first 3–4 months of
treatment. In severe persistent asthma systemic adminis-
tration of corticosteroids may be required to control
symptoms, but its use is limited by the risk of significant
adverse side effects, such as glaucoma, cataracts, de-
creased bone mineral density, obesity and adrenal suppres-
sion,1 which are less prominent during ICS treatment.3
Besides the established potential in reducing asthma-
related symptoms and improving pulmonary function, little
is known about the influence of ICS on the perception of
dyspnea, which is a cardinal symptom of asthma. Dyspnea is
the subjective experience of breathing discomfort that
originates from interactions among various physiological,
psychological, social and environmental factors.4 The
adequate perception of onset and severity of dyspnea is an
important aspect of disease self-management programs,1
because a failure to perceive the severity of a developing
bronchoconstriction and associated dyspnea might result in
ineffective or delayed treatment. Blunted perception of
dyspnea has been reported in subgroups of patients with
asthma5,6 and has been shown to be associated with
inadequate use of medication, frequent re-hospitalizations,
near-fatal and even fatal attacks.6–9 Therefore, it is of
utmost importance to know whether the commonly pre-
scribed corticosteroids have a specific influence on this
perceptual process in asthma. With respect to this several
pathways have been suggested by which corticosteroids
might influence the perception of bronchoconstriction and
associated dyspnea,10 including the reduction of inflamma-
tory processes in the airways, restoration of the epithelial
structure and effects on the central nervous system.
The present paper provides an overview of the current
knowledge concerning the influences of corticosteroids on
the perception of dyspnea in asthma. Studies were selected
from literature searches in relevant databases (PubMed,
PsycINFO and Embase) using the terms corticosteroids or
steroids, dyspnea or breathlessness and asthma as well as
their combinations. Additional studies were identified by
searching bibliographies of retrieved studies. We limited the
search to English-language articles published from January 1,
1980 to September 30, 2005. Included studies had to test the
sensitivity to perceive different levels of airflow limitation
in asthmatic or healthy participants who were treated with
inhaled or systemic corticosteroids. Studies merely demon-
strating changes in reported dyspnea after corticosteroidtreatment, but without specifically testing the perception of
different levels of airflow limitation, were not included,
because these do not allow conclusions to be drawn about
perceptual sensitivity. Moreover, potential mechanisms
underlying the relationship between corticosteroids and
perception of dyspnea are presented and implications for
future research are provided.
Direct mechanisms of corticosteroids
Corticosteroids have both direct, rapid, non-genomic effects
such as binding to receptors and indirect, genomically
mediated effects like repression of gene transcription. They
decrease the number of inflammatory cells in the airways,
including T-lymphocytes, eosinophils, mast cells and den-
dritic cells. These effects are achieved through the
inhibition of the recruitment of inflammatory cells into the
airway by suppressing the production of chemotactic
mediators and adhesion molecules and by inhibiting the
survival of inflammatory cells, including T-lymphocytes,
eosinophils and mast cells, in the airways.11 These inflam-
matory processes in asthma have been assumed to damage
sensory receptors in the airways, which could reduce the
perception of bronchoconstriction.12 Thus, corticosteroids
might improve the perception of dyspnea in asthma by their
broad range of anti-inflammatory effects. Furthermore, it
has been assumed that corticosteroids can lead to a
restoration of the integrity of the airway epithelium.13 In
turn, this may reduce intraepithelial nerve injury or
increase the production of epithelial-derived mediators
being involved in the activation of airway sensory recep-
tors.12 Because epithelial cells in particular may be a major
cellular target for ICS,11 the restoration of the airway
epithelial structure has been suggested as another mechan-
ism by which corticosteroids might improve the perception
of dyspnea10,12 (see Fig. 1).
Indirect mechanisms of corticosteroids
In addition to the intentional anti-inflammatory effects and
known adverse physiologic side effects of corticosteroids,
many adverse psychological effects have been reported in
children and adults, including symptoms of depression,
mania, psychosis and behavioral and cognitive deficits.14–16
These were particularly prominent for systemic corticoster-
oids but also occurred during treatments with ICS, which,
however, have been less well examined in this regard. Brown
et al.17 demonstrated that even brief courses of oral
prednisone in modest concentrations lead to symptoms of
mania and depression in patients with asthma. The under-
lying mechanisms are still not well examined but are likely
to involve a complex interplay between disease related
characteristics, individual predispositions, distressing envir-
onmental aspects and pharmacokinetic properties of the
administered corticosteroid.14 The latter include varying
effects on the neurotransmitters serotonin and dopamine in
many different regions of the brain. Particularly hippocam-
pal damage has been assumed to play an important role in
the mediation of adverse psychological effects of systemic
corticosteroids.14,18 Since research has shown that negative
affectivity is related to inadequate perception of asthma
ARTICLE IN PRESS
CORTICOSTEROIDS 
Direct Mechanisms Indirect Mechanisms
broad anti-   restauration of  adverse physiologic adverse psychological 
inflammatory effects  airway epithelium side effects side effects
PERCEPTION OF DYSPNEA
Figure 1 Schematic presentation of possible direct and indirect mechanisms of corticosteroids on the perceptual sensitivity for
dyspnea. Dotted arrows indicate an absence of studies examining the assumed mechanism.
Corticosteroids and perception of dyspnea 1081symptoms such as dyspnea,19–21 it can be assumed that
corticosteroid-related adverse symptoms, such as depres-
sion or mania, interfere with an accurate perception of
dyspnea (see Fig. 1). Besides blunted perception of dyspnea
also an over-perception could occur which might be related
with over-treatment.19,20 However, no systematic research
on the interrelationships between inhaled or systemic
corticosteroids, psychological symptoms and resulting per-
ception of dyspnea is available. In addition, it is unknown
whether other adverse side effects of corticosteroids, such
as glaucoma, cataracts or decreased bone mineral density
have a further influence on the perception of dyspnea.
However, it may be speculated that the burden of these
chronic disease conditions leads to increased psychological
symptoms (e.g., depression), which, in turn, may interfere
with the perception of dyspnea.ICS and perception of dyspnea
In the following studies are reviewed that examined the
influence of ICS on the sensitivity to perceive dyspnea
(Table 1). The first study in this area was performed by
Roisman et al.12 They investigated patients (mostly steroid-
naive, i.e. not receiving steroids at study enrollment) with
mild to moderate asthma who were randomly treated for 4
weeks with inhaled b2-agonists given either alone (n ¼ 9) or
in combination with 1000 mg flunisolide twice daily (n ¼ 9).
After treatment all patients underwent bronchoalveolar
lavage and bronchial biopsies as well as a methacholine and
bradykinin challenge during which perceived dyspnea was
rated on a visual analog scale after each dose of the inhaled
bronchoconstrictive agent. The results showed that ICS
treatment led to increased sensitivity for bradykinin induced
dyspnea, which is an endogenous inflammatory mediator in
asthma. Moreover, the authors demonstrated correlations
between inflammatory status and perception of induced
dyspnea such that stronger eosinophilic inflammation and
epithelial damage are associated with reduced perception
of dyspnea.
In a study by Boulet et al.10 15 patients with mild asthma
who used bronchodilators only were compared with 15patients with moderate asthma who received a daily dose of
inhaled beclomethasone equivalent of 400–1500 mg. During
the study both groups received either 50 mg of the b2-agonist
salmeterol or placebo over the course of 4 weeks, separated
by a 2-week wash-out period. The perception of dyspnea
was measured on a Borg scale during methacholine
challenges before and after the treatments. It was found
that the patients who used ICS showed a more sensitive
perception of dyspnea during methacholine challenges than
the patients who only received salmeterol. The perceptual
sensitivity was stable throughout the treatment period and
was not influenced by additional use of salmeterol. Atopic
patients in both groups demonstrated a reduced perception
of dyspnea compared to non-atopic individuals.
Weiner et al.22 assessed 47 steroid-naive patients with
moderate asthma who received 250 mg fluticasone twice
daily for 8 weeks while 20 matched patients received a
placebo. Before and after treatment participants had to
rate their sensation of dyspnea on a modified Borg scale
while breathing against progressive resistances aimed to
induce mouth pressures of 0, 5, 10, 20 and 30 cm H2O.
Following 8 weeks of treatment, 32 patients in the
fluticasone group improved their FEV1 by more than 15% of
the predicted value. The other 15 patients in the fluticasone
group as well as all patients in the placebo group did not
reach similar improvements. Only those patients in the
fluticasone group who showed an improved lung function
also showed increased perception of dyspnea in terms of
higher dyspnea ratings during breathing against progressive
resistances when compared to pre-treatment. The flutica-
sone-treated patients without improved FEV1 as well as the
placebo group showed no significant change in their
perception of dyspnea. The authors conclude that ICS
treatment results in improved perception of dyspnea, but
only if concomitant improvements in airflow are obtained.
Similar results were reported by Bijl-Hofland et al.23 They
allocated 128 steroid-naive patients with mild–to moderate
asthma to 3 groups, which received regular treatment with
either salbutamol (200 mg/d QID), formoterol (12mg/d BID)
or placebo over a course of 12 weeks. Exactly 1 year later, 64
of these patients received the same treatment for a further
12 weeks but in combination with 400 mg beclomethasone
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Table 1 Studies examining the influence of ICS on the perception of dyspnea in patients with asthma.
Author Patients/
controls
ICS treatment Method of
dyspnea
induction
Effect on
dyspnea
perception
Markers of
inflammation
and dyspnea
perception
Effect size d
for major
finding
Roisman et al.12 9/9 1000 mg
flunisolide
Methacholine
and
bradykinin
challenge
m For bradykinin
challenge but
not for
methacholin
kk 0.59
Boulet et al.10 15/15 400–1500 mg
beclomethasone
equivalent
Methacholine
challenge
m Not studied 2.96
Weiner et al.22 47/20 250 mg
fluticasone
Breathing
against
progressive
resistances
m Only when
FEV1 increased
in parallel
Not studied Insufficient
report of
numeric data
Bijl-Hofland et al.23 64 400 mg
beclomethasone
Histamine
challenge
m When
combined with
LABA
Not studied 0.58
Salome et al.24 35 1600 or 3200 mg
budesonide with
subsequent
downtitration
Histamine
challenge
m kk in
circulating
eosinophils, no
effect with
serum eosin.
cationic protein
0.57
Salome et al.25 33 50% reduction of
ICS dose
Mannitol
challenge
k Parallel
increase in
sputum
eosinophils but
statistically not
significant
0.40
Higgs and Laszlo27 12 100 mg
beclomethasone
Self-
estimation of
dyspnea
during
everyday life
k Not studied 1.07
in’t Veen et al.28 30/11 500 mg
fluticasone
Methacholine
and
hypertonic
saline
challenge
k For bradykinin
but not for
hypertonic
saline
kk In severe
ICS-dependent
patients; mm in
mild, steroid-
naive patients
Insufficient
report of
numeric data
Ottanelli et al.29 55/45 800 mg of not
further
specified ICS
Methacholine
challenge
k kk In patients
receiving ICS;
mm in ICS-naive
patients
0.15
m(k): Increased (decreased) sensitivity to perception of dyspnea; mm (kk): Stronger inflammation associated with increased
(decreased) sensitivity to perception of dyspnea; FEV1: forced expiratory volume in 1 s; ICS: inhaled corticosteroids; LABA: long acting
b2-agonist.
A. von Leupoldt et al.1082dipropionate BID. Before, during and after treatment
periods in both years the perception of dyspnea was
assessed on a Borg scale during histamine challenges. The
results showed that adding ICS to a long acting b2-agonist
but not to a short acting b2-agonist improves the perceptual
sensitivity to histamine induced dyspnea after 4 weeks of
treatment. There was a tendency for similar improvements
in the group that received ICS in addition to the placebo.
In a further study by Salome et al.24 35 patients with
poorly controlled moderate asthma were recruited andrandomly assigned to groups that received either 1600 or
3200 mg/day budesonide for 8 weeks, followed by 8 weeks of
1600 mg/day budesonide and a subsequent down-titration
for 56 weeks. The perception of dyspnea was measured on a
Borg scale during histamine challenges performed at base-
line and after 8, 16, 24, 48 and 72 weeks of treatment. At
baseline there was no difference in perception between the
17 patients using ICS (mean ICS use of 975 mg BDP equivalent)
and the 18 patients not using ICS. After 8 weeks of
treatment perception of induced dyspnea increased without
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sonide and the group receiving 3200 mg/day. This improve-
ment was only weakly associated with decreased
inflammatory status in terms of circulating eosinophils, but
not with systemic levels of airway inflammation in terms of
serum eosinophil cationic protein. The results obtained from
the 20 patients who completed the full 72-week follow-up
period showed that the improved perception remained
stable after the first 8 weeks of treatment but without
further improvements.
In another study by the same group25 the opposite
strategy to an administration of ICS was used. From a
preliminary sample of 42 patients with well-controlled
asthma 33 patients successfully halved their ICS dose
without developing an exacerbation during the following 8
weeks. Perception of dyspnea was measured with a Borg
scale before and at monthly intervals after the dose
reduction during a bronchial challenge with mannitol
together with an assessment of the inflammatory status of
the airways by measuring exhaled nitric oxide and sputum
inflammatory cells. Results after 8 weeks indicated that a
reduction of ICS decreased the sensitivity to perceive
dyspnea induced by mannitol challenge. This was paralleled
by increases in sputum eosinophils, which, however, were
not significantly correlated with the changes in perception
of dyspnea. Notably, the decrease in perception of dyspnea
during mannitol challenges after reducing the dose of ICS
occurred before any decline of baseline lung function or
asthma exacerbation could be measured over the course of
the study. Thus, the changes in perception seem unlikely to
be a result of adaptation processes to slowly developing
bronchoconstrictions, which have been suggested to be
associated with blunted perception of dyspnea.26
While all of the above studies have reported some
improvement in the perception of dyspnea following ICS
treatments, others have found contrary results. In a study by
Higgs and Laszlo27 12 steroid-naive patients with poorly
controlled asthma received 100 mg beclomethasone four
times daily for 2 weeks, 2mg cromoglycate four times daily
for 2 weeks and theophylline twice daily for 4 weeks to
achieve blood levels between 10 and 20mg/L. Treatments
were separated by 1 week wash-out periods. In the second
week of each treatment participants estimated their
perceived asthma symptoms three times daily on a visual
analog scale followed by a self-measurement of PEF. The
results showed that cromoglycate slightly improved PEF and
slightly decreased perceived symptoms of asthma. The
perception of asthma symptoms, as measured by the
relationship between PEF and visual analog scores, however,
was unaffected by cromoglycate. Theophylline increased
the perceived symptoms of asthma despite improvements in
lung function. Most importantly for this review, beclometha-
sone reduced the perception of asthma symptoms without
concomitant improvements in lung function.
These data were mirrored by results of in’t Veen et al.28
They showed that dyspnea during a methacholine challenge
was less well perceived by 30 patients with severe asthma,
receiving 500 mg fluticasone twice daily for at least 4 weeks,
compared to 11 patients with mild asthma not using ICS. No
difference in the respective ratings on Borg scales and visual
analog scales was found when the perception of dyspnea was
measured during a bronchial challenge with hypertonicsaline. The reduced sensitivity to the perception of dyspnea
in severe ICS-dependent patients with asthma was corre-
lated with greater inflammation of the airways in terms of
increased sputum eosinophils while in mild steroid-naive
patients with asthma the reverse association was obtained.
Similar findings were obtained by Ottanelli et al.29 in
patients with stable mild or moderate asthma. They compared
55 patients who were receiving approximately 800mg of not
further specified ICS with 45 ICS-naive patients. For further
analyses both groups were subdivided into obstructed (FEV1/
VC percentage ratio o70%) and non-obstructed (FEV1/VC
percentage ratio470%) patients. All participants underwent a
sputum induction to measure eosinophils as well as a
methacholine challenge during which perception of dyspnea
was measured on a visual analog scale. The results demon-
strated that patients treated with ICS had a lower perception
of dyspnea than ICS-naive patients. Similar to the findings by
in’t Veen et al.28 greater inflammation was associated with
decreased perception in patients receiving ICS, but with
increased perception in ICS-naive patients. In contrast to the
findings discussed above,10,12,22–25 the authors conclude that
airway inflammation might be associated with improved
perception of dyspnea.
Systemic corticosteroids and perception of
dyspnea
Two further studies have examined the influences of
systemic treatment with corticosteroids on symptom per-
ception. Noseda et al.30 studied the effects of intravenous
administration of 125mg methylprednisolone or a placebo
on two consecutive days in 18 symptomatic steroid-
dependent patients with asthma. FEV1 and perception of
dyspnea were measured on a bipolar visual analog scale
5min and 60min after administration of the respective
agent and after a succeeding inhalation of 2 500 mg
terbutaline at 65 and 90min. Results showed that the
injection of methylprednisolone did not differ from that of
the placebo in terms of dyspnea ratings. Both reduced the
perception of dyspnea in the absence of significant changes
in lung function. Furthermore, methylprednisolone had no
effect on the perception of subsequent bronchodilation
induced by terbutaline.
Kallas de Carvalho et al.31 examined the effect of oral
administration of either 40mg prednisone or a placebo on
perceived dyspnea 6 h later in 16 healthy young participants
on two separate days. Perception of dyspnea was assessed
on a visual analog scale while participants breathed through
inspiratory resistive loads of different magnitudes and by
measuring the maximal time that participants could hold
their breath. It was shown that during resistive load
breathing oral prednisone had no effect on the perception
of dyspnea when compared to the placebo. Although the
time participants could hold their breath was 10% longer
than after the administration of the placebo, this difference
did not reach statistical significance.
Discussion
Corticosteroids, particularly ICS, are highly effective anti-
inflammatory medications and have been recommended as
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Dyspnea is a cardinal symptom in these patients and should
be recognized early to allow adequate and immediate
treatment especially since blunted perception of this
symptom has been shown to be associated with poor
treatment outcome including fatal attacks.6–9 In light of
these facts, it is striking that our knowledge of the influence
of corticosteroids on patients’ perception of dyspnea is
considerably limited. Although recent studies with large
numbers of patients32–34 have demonstrated the beneficial
effects of corticosteroids on improving lung function,
increasing quality of life and reducing symptoms, including
dyspnea, their effects on the sensitivity to perceive dyspnea
has rarely been examined.
For the present review only 11 studies could be identified
that examined this important relationship with differing
experimental designs. Of these, 9 reports studied the
effects of ICS10,12,22–25,27–29 while only 2 further studies
focused on either intravenous30 or oral corticosteroids.31 In
6 studies on the effects of ICS it was shown that they are
associated with improvements in the perception of dys-
pnea,10,12,22–25 but 3 studies demonstrated contrary re-
sults.27–29 A single intravenous administration of
corticosteroids was associated with reduced perception of
dyspnea30 while a single oral dose showed no effect.31 Thus,
neither for ICS nor for systemic corticosteroids firm
conclusions on their influence on the perception of dyspnea
could be drawn on the basis of the available experimental
data which are often limited or not comparable in
methodology (e.g. tested medication, size and character-
istics of the samples, instruments for dyspnea induction and
measurement).
The same holds for the mechanisms that might underlie
the relationship between corticosteroids and perception.
While some studies have suggested that increased sensitivity
to perception of dyspnea might be related to reduced airway
inflammation due to the anti-inflammatory effects of
ICS,12,24,25 others have shown an increase in perception
with increased inflammatory status.28,29 However, most of
the reviewed investigations have not examined the con-
comitant changes in inflammatory markers during the tests
of perception.
Furthermore, no information is available about the
influence of psychological aspects on the perception of
dyspnea during corticosteroid treatments. These have been
assumed as additional mechanism influencing the perception
of dyspnea due to adverse psychological side effects of
inhaled and particularly systemic corticosteroids, e.g.,
depression, anxiety or mania. Although this potential
mechanism has been mentioned in most of the reviewed
studies, no study has reported any measure to control for
psychological effects of the respective treatments. More-
over, in light of these known side effects it is remarkable
that only one study has reported a history of psychiatric
disorders being an exclusion criteria, but without specifying
the method of assessment.30
In addition to considerable differences in the experi-
mental methodologies the contradicting findings reported
above might have partly been caused by shortcomings in the
designs. Also, these facts in combination with the limited
number of available studies were preventing a more
stringent systematic review. However, defined criteria andan acceptable systematic strategy were used for the present
paper, thus leading to an extensive overview on this
important topic including information on all current
methodological shortcomings and related implications for
future research.
Overall, it can be assumed that the small sample sizes of
many of the reported studies might have provided insuffi-
cient test power to detect true differences between
examined groups or treatments (see Table 1). Further,
patients with varying durations of asthma as well as levels of
disease severity were included in the studies, often without
mentioning the criteria used for asthma classification. The
degree of severities ranged from stable mild to poorly
controlled severe asthma with one study examining a
healthy population. Since the degree of asthma has been
shown to be associated with the perceptiveness of
dyspnea,35 this variability might have contributed to the
contradicting results. The same holds for the duration of
asthma. In patients with a longer history of disease the
threshold for the detection of dyspnea might have changed
over time, which has been discussed as ‘temporal adapta-
tion’ in the literature.26 In addition, all studies exclusively
examined adult patients.
Moreover, the studies varied considerably in the medical
treatments that were studied. While some studies only
examined corticosteroids others compared or combined ICS
with different bronchodilators. Other investigations com-
pared effects of the treatments patients were already
receiving, but without administering a specific drug in a
controlled fashion. Although all studies except one28 were
specifically aimed to evaluate the influence of corticoster-
oids on the perception of dyspnea (i.e., either as single
treatment or in comparison to other treatments), it cannot
be excluded that examining corticosteroids in combination
with or in within-subject comparisons to other bronchodi-
lative treatments leads to different results than evaluating
the isolated effects of corticosteroids. Further, the study by
in’t Veen et al.28 examined the specific impact of the
severity of asthma on the perception of dyspnea. Although
patients receiving ICS were compared in a controlled design
with an ICS-naive group, conclusions on the effects of ICS
were limited by differences in the severity of asthma
between groups. Furthermore, treatments differed in terms
of the prescribed doses and in the duration of medication.
The latter ranged from a single bolus to 72 weeks, with the
majority of regimens lasting about 4–8 weeks. Thus, with
the exception of Salome et al.’s24 findings little is known
about long-term effects on the perception of dyspnea. Since
corticosteroid treatments do not act immediately on the
airways (like short- or long-acting bronchodilators do),
different treatment durations might differentially allow
their beneficial as well as side effects to develop. This could
lead to subsequent differences in their impact on the
sensitivity to perceive dyspnea. In addition, it is not known
whether there are differences in the impact on perception
between distinct drugs of the same pharmacological class,
i.e., between different ICS. Furthermore, it is difficult to
distinguish between the isolated effect of the corticosteroid
treatment in the discussed investigations and confounding
effects of varying additional medication. All studies allowed
their patients to use rescue medication as needed, mostly
b2-agonists, which were often neither described neither
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reported to impact on the perception of dyspnea,36 a topic,
which would be worthy of its own review, interactions with
the effects of corticosteroid treatments might be assumed.
In addition, there have been differences both within and
between the studies concerning the duration of the
patients’ prior medical regimens, which could have further
influenced the results.
A variety of techniques to induce dyspnea have been used
in the reported studies. In most cases challenge tests with
bronchoconstrictive agents such as methacholine, hista-
mine, bradykinin, mannitol and hypertonic saline were
employed with reductions in lung function being measured
in terms of the FEV1 after each dose of administered agent.
Others have used resistive load breathing to induce airflow
limitation, while in a few studies patients rated their level
of dyspnea several times a day while actual changes in lung
function were measured with a peak flow meter. Previous
studies, however, have shown that there are considerable
differences in the perception of induced bronchoconstric-
tion between different provocative agents.37,38 Different
techniques for the induction of dyspnea have also been
shown to be unequally sensitive in detecting reduced
perception of dyspnea in patients.39 This might be explained
by the stimulation of different receptors with different
agents and techniques, which adds to the limited compar-
ability between the discussed studies. Moreover, one of the
two studies using resistive loads31 did not weight the
imposed loads for the total resistance of participants, which
is the sum of external resistive loads and internal,
physiological resistive loads. Therefore, the same external
resistive load is not comparable between participants with
different levels of bronchial obstruction, which could have
influenced the outcome. In addition, the assessment of
different levels of lung function in terms of PEF self-
measurements in every-day life contains the risk of poor
compliance and poor technical quality,40,41 which, in
addition to learning effects due to daily self-estimation of
dyspnea, might have negatively influenced results.
A similar variability has been used in the reported studies
to measure the perception of dyspnea. Most studies
employed validated rating scales (e.g., the Borg scale or
visual analog scales) and plotted the ratings against the
obtained fall in either FEV1 or PEF. Some studies quantified
the perception in terms of the slope of the linear regression
between ratings and lung function, while others used the
intercept, the absolute magnitude at a 20% fall in lung
function, the mean rating scores or a mixture of the
measures. These quantifications partly showed different
results in the same study subjects,24,28 therefore they might
assess different aspects of perception and might not be
comparable. In addition, the rating instructions and defini-
tions of dyspnea varied considerably between studies and all
studies measured dyspnea on a global level. None of the
studies measured distinct sensory or affective aspects in the
perception of dyspnea, but previous research has shown that
these aspects can be differentiated by subjects.42–45 Thus,
no information is available on how corticosteroids might
differentially affect these distinct aspects in the perception
of dyspnea.
Overall, it has been questioned whether assessments of
dyspnea ratings during both challenge tests and resistiveload breathing are adequate paradigms to measure the
sensitivity to perceive dyspnea.46,47 However, since no gold-
standard is available in this respect, it should be kept in
mind that both techniques try to mimic asthmatic dyspnea
in the laboratory and therefore might not necessarily mirror
an asthmatic exacerbation under real-life conditions.48Implications for future research
It has been shown above that corticosteroids are not only
effective in controlling symptoms of asthma but might also
influence the perception of dyspnea; presumably due to
their anti-inflammatory and/or psychological side effects. It
is, however, obvious from the discussed findings that more
studies with adequate methodologies are needed to allow
firm conclusions to be drawn concerning perceptual effects
and their underlying mechanisms. Future studies on corti-
costeroids should include tests of the effects on the
perception of dyspnea and comparisons between patients
groups should not be confounded with a priori differences in
age, gender, ethnicity, history of prior medication, disease
severity and duration of asthma. Rather, specifically planned
comparisons between these different groups could yield
additional information about potential differences in the
relationship between corticosteroids and perception, which
are related to the above factors. Furthermore, future
studies should control for the confounding effects of other
medications, which are used in addition to corticosteroids,
i.e., bronchodilative rescue medication.1 Since a complete
abstinence from these medications during study periods is
not possible in most circumstances, only one substance
should be prescribed and the daily use measured, reported
and controlled for in statistical analyses. Moreover, differ-
ences in beneficial effects as well as side effects between
different corticosteroids and between different doses have
been reported.1 Therefore, possible effects of different
substances or doses on the perceptiveness of dyspnea might
be compared in future investigations. In any case, it is
necessary to examine the long-term effects of these
regimens, since changes in the course of treatment might
occur. With regard to the aforementioned adverse psycho-
logical side effects of inhaled and particularly systemic
corticosteroids, participants in future studies should be
screened for existing psychological comorbidities before the
commencement of studies. Psychological variables, e.g.,
depression, mania, anxiety, irritability or cognitive func-
tioning should be monitored during study periods and
subsequently analyzed in terms of possible changes during
corticosteroid treatment and their relation to the sensitivity
to perceive dyspnea. To account for such effects, sensory
and affective aspects in the perception of dyspnea should be
differentiated in studies by using separate rating instru-
ments.49–51 This would provide more precise conclusions
about which specific aspects of perceived dyspnea are
influenced by medical treatment or by possible psychologi-
cal side effects.42 Furthermore, future investigations should
measure concomitant changes in inflammatory markers
during corticosteroid treatments. This would help establish-
ing whether potential effects on the perception are related
to changes in inflammatory processes within the airways due
to corticosteroid treatments. In addition, it may be
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of corticosteroids (e.g., glaucoma, cataracts or decreased
bone mineral density) are related to the perception of
dyspnea. Finally, since the presented studies in this area
were exclusively performed in adult participants, future
studies are required in children with asthma.
Conclusions
Corticosteroids are effective and recommended anti-inflam-
matory medications for controlling asthma. Dyspnea is a
cardinal symptom in asthma and its adequate perception is
important for successful treatment. Inadequate perception
of this symptom is associated with poor treatment outcome
including fatal attacks, but little is known about the
influence of corticosteroid treatments on this perceptual
process. It has been suggested that corticosteroids might
influence the perception due to their broad anti-inflamma-
tory effects within the airways. Alternatively, related
adverse psychological side effects have been assumed to
lead to changes in the perception of the sensation of
dyspnea. However, only a few studies in adult patients have
examined these questions, predominantly focusing on ICS.
While some of these studies showed that ICS are associated
with the positive effect of improved perception of dyspnea
others demonstrated the negative contrary. Systemic corti-
costeroids showed either no effect or were related to
reduced perception. Further, the obtained results could
neither be consistently explained by inflammatory processes
nor by psychological mechanisms, which have not been
examined in the available studies. The conflicting findings
might have been caused by considerable differences in
experimental methodology between studies. Overall no firm
conclusions could be drawn from the limited experimental
data. Future studies with improved designs are required to
better understand the influence of corticosteroids on the
perception of dyspnea.
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